http://www.therapeuticsdaily.com/news/summary.cfm?id=1843206&channelID=31

Phase IIa Data on TMC435350 in Patients with Hepatitis C to be Presented at
AASLD

Cision (English) - 24-Sep-2008
TMC435350 is an investigational protease inhibitor, being developed by Tibotec
in partnership with Medivir, for the treatment of hepatitis C virus (HCV).
OPERA-1 is currently recruiting patients to evaluate higher doses in
treatment-naοve HCV patients, as well as those who have not responded or have
relapsed on previous SoC treatment.


Summary
• Medivir today announced that three abstracts related to TMC435350 have been
accepted for poster presentations at the upcoming 59th Annual Meeting of the
American Association for Study of Liver Diseases (AASLD) meeting in San
Francisco October 31 - November 4.
• The abstracts for these presentations have been published today and are
available on Hepatology web site (AASLD).
• TMC435350 is an investigational protease inhibitor, being developed by Tibotec
in partnership with Medivir, for the treatment of hepatitis C virus (HCV).
• Clinical results from the ongoing phase IIa trial (OPERA-1) will be presented
in two posters and a third poster will present preclinical results.
• The phase IIa proof-of-concept trial (OPERA- 1) is a blinded, randomized and
placebo-controlled trial to assess the antiviral activity, safety and
pharmacokinetics of once-daily (QD) regimens of TMC435350 in HCV genotype 1
patients.
• Results from Cohort 1, 25mg or 75mg TMC435350 versus placebo, will be reported
at AASLD
• ?These data demonstrate the potent antiviral activity of TMC435350 against
genotype-1 HCV?, says Lars Adlersson, CEO & President at Medivir. ?
• Based on these clinical and non-clinical studies, we are confident that
TMC435350 has the potential to become a valuable addition to available therapy,
providing an efficacious treatment with once-daily dosing?.